| Name | Title | Contact Details |
|---|
Fatima Group is one of the largest business conglomerates in Pakistan operating in diversified sectors like Fertilizers, Textiles, Sugar, Energy, Packaging, Mining & Trading of commodities. Established in 1936 with trading of commodities and gradually entered into the manufacturing of various products. The Group has a success story spread over seven decades, expanding its horizon from trading to manufacturing. With an annual turnover of over 80 billion PKR and more than 6,300 employees, Fatima Group plays an important role in the economic development of the country.
AI REV is a boutique AI consulting company with partners having extensive practical AI experience and strong track records. We provide state-of-the-art consulting & AI project delivery for enterprise clients. AI REVs goal is to reduce the average human workweek from 40 hours to 20. We are working towards achieving this by augmenting companies with AI-powered efficiency improvements. Our solutions have saved our customers up to 25% on related departamental costs, substantially decreased their operational risk, and enabled the reallocation of manpower to more pressing issues. We offer end-to-end Machine Learning, Data Science, AI & software development, Strategic Consulting, and Engineering Workshops.
Kerrie Kelly is a multifaceted design studio bringing thoughtful design into everyday life. To work with Kerrie Kelly—whether through residential interiors, corporate partnerships or lifestyle entertainment—is to gain a trusted, industry-savvy partner who bridges the gap between design principles and a life well lived.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.